A. Chemaissani

Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial.

K. Dalhoff, L. Edler, T. Walter, 2001, European journal of cancer.

Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.

R. Stahel, S. Ricci, J. von Pawel, 1999, Lung cancer.

Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.

R. Stahel, S. Ricci, P. Kellokumpu-Lehtinen, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.

S. Ricci, J. von Pawel, P. Kellokumpu-Lehtinen, 1997, Seminars in oncology.

Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin.

Michael Schroeder, Christian Schumann, C. Schumann, 2006, Clinical lung cancer.

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.

J. Bogaerts, U. Gatzemeier, R. Pirker, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.

A. Favero, B. Duclos, F. Cognetti, 1996, European journal of cancer.

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

P. Ellis, T. Welte, M. Ranson, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.